Literature DB >> 21750502

Prostate cancer: PSA velocity in prostate cancer screening--the debate continues.

Michael S Borofsky, Danil V Makarov.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21750502     DOI： 10.1038/nrurol.2011.87

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Authors:  Ian M Thompson; Donna Pauler Ankerst; Chen Chi; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Ziding Feng; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-04-19       Impact factor: 13.506

2.  Experts debate utility of PSA velocity as a criterion for prostate biopsy.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

3.  NCCN clinical practice guidelines in oncology: prostate cancer early detection.

Authors:  Mark H Kawachi; Robert R Bahnson; Michael Barry; J Erik Busby; Peter R Carroll; H Ballentine Carter; William J Catalona; Michael S Cookson; Jonathan I Epstein; Ruth B Etzioni; Veda N Giri; George P Hemstreet; Richard J Howe; Paul H Lange; Hans Lilja; Kevin R Loughlin; James Mohler; Judd Moul; Robert B Nadler; Stephen G Patterson; Joseph C Presti; Antoinette M Stroup; Robert Wake; John T Wei
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

4.  Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.

Authors:  Leon Sun; Judd W Moul; James M Hotaling; Edward Rampersaud; Phillipp Dahm; Cary Robertson; Nicholas Fitzsimons; David Albala; Thomas J Polascik
Journal:  BJU Int       Date:  2007-01-19       Impact factor: 5.588

5.  An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.

Authors:  Andrew J Vickers; Cathee Till; Catherine M Tangen; Hans Lilja; Ian M Thompson
Journal:  J Natl Cancer Inst       Date:  2011-02-24       Impact factor: 13.506

6.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability.

Authors:  H Ballentine Carter; Luigi Ferrucci; Anna Kettermann; Patricia Landis; E James Wright; Jonathan I Epstein; Bruce J Trock; E Jeffrey Metter
Journal:  J Natl Cancer Inst       Date:  2006-11-01       Impact factor: 13.506

Review 7.  Inventory of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Pierre I Karakiewicz; Vitaly Margulis; Michael W Kattan
Journal:  Curr Opin Urol       Date:  2008-05       Impact factor: 2.309

8.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Kimberly A Roehl; William J Catalona
Journal:  N Engl J Med       Date:  2004-07-08       Impact factor: 91.245

9.  Prostate specific antigen best practice statement: 2009 update.

Authors:  Kirsten L Greene; Peter C Albertsen; Richard J Babaian; H Ballentine Carter; Peter H Gann; Misop Han; Deborah Ann Kuban; A Oliver Sartor; Janet L Stanford; Anthony Zietman; Peter Carroll
Journal:  J Urol       Date:  2009-09-24       Impact factor: 7.450

10.  Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Authors:  Pär Stattin; Erik Holmberg; Jan-Erik Johansson; Lars Holmberg; Jan Adolfsson; Jonas Hugosson
Journal:  J Natl Cancer Inst       Date:  2010-06-18       Impact factor: 13.506
  10 in total
  1 in total

1.  Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor.

Authors:  Po-Yuan Lin; Kai-Lun Cheng; James D McGuffin-Cawley; Fuh-Sheng Shieu; Anna C Samia; Sanjay Gupta; Matthew Cooney; Cheryl L Thompson; Chung Chiun Liu
Journal:  Biosensors (Basel)       Date:  2012-09-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.